Form 4: BIOXYTRAN Director Buys Preferred Shares

Sentiment:

Insider Transaction Report


BIOXYTRAN Director Anders Utter acquired 38,588 preferred shares at $0.35, increasing his beneficial ownership to 372,580 shares.

Summary

  • Anders Utter, a Director of BIOXYTRAN, INC (BIXT), acquired 38,588 preferred shares.
  • The transaction occurred on November 14, 2025, at a price of $0.35 per share.
  • Following this acquisition, Mr. Utter beneficially owns 372,580 preferred shares.
  • The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The acquisition of company shares by a director is generally viewed as a positive signal of confidence in the company's future prospects, although the specific nature of preferred shares and the relatively low price warrant careful consideration.

Positives

  • A Director's acquisition of company shares signals confidence in the company's future prospects.
  • The purchase increases insider ownership, potentially aligning management interests with shareholders.

Negatives

  • The shares acquired are 'preferred,' which may have different rights or liquidity compared to common stock.
  • The transaction price of $0.35 per share is relatively low, which could indicate a low valuation or specific terms for preferred shares.

Future Outlook

N/A. This filing reports a past transaction and does not provide forward-looking statements or guidance.

Industry Context

N/A. This Form 4 filing is specific to an individual insider transaction and does not provide broader industry context.

Related Party Transactions

  • Anders Utter, a Director of BIOXYTRAN, INC, acquired preferred shares from the company, which constitutes a related party transaction.

Stakeholder Impact

  • Shareholders may interpret the director's purchase as a positive indicator of management's belief in the company's value and future performance.
  • Increased insider ownership can enhance alignment between management and shareholder interests.

Key Dates

DateDescription
11/14/2025Transaction Date: Acquisition of preferred shares by Anders Utter.
11/18/2025Filing Date: Signature date of the Form 4 by Anders Utter.

Keywords

BIOXYTRAN, BIXT, Insider Trading, Form 4, Director Purchase, Preferred Shares, Anders Utter, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.